- Report
- October 2024
- 193 Pages
Global
From €3464EUR$3,545USD£2,892GBP
€3849EUR$3,939USD£3,213GBP
- Report
- August 2024
- 136 Pages
Global
From €3810EUR$3,899USD£3,180GBP
- Report
- November 2024
- 372 Pages
Global
From €5325EUR$5,450USD£4,445GBP
- Report
- May 2024
- 100 Pages
Africa
From €1954EUR$2,000USD£1,631GBP
- Report
- April 2024
- 80 Pages
United States
From €1466EUR$1,500USD£1,224GBP
- Report
- November 2024
- 546 Pages
Global
From €6834EUR$6,995USD£5,706GBP
- Report
- October 2024
- 188 Pages
Global
From €3464EUR$3,545USD£2,892GBP
€3849EUR$3,939USD£3,213GBP
- Report
- November 2024
- 158 Pages
Global
From €5325EUR$5,450USD£4,445GBP
- Report
- November 2024
- 89 Pages
Global
From €5471EUR$5,600USD£4,568GBP
- Report
- January 2024
- 200 Pages
Global
From €4885EUR$5,000USD£4,078GBP
- Report
- January 2024
- 200 Pages
Global
From €3908EUR$4,000USD£3,263GBP
- Report
- September 2024
- 187 Pages
Global
From €4397EUR$4,500USD£3,671GBP
- Report
- January 2024
- 182 Pages
Global
From €4397EUR$4,500USD£3,671GBP
- Report
- July 2024
- 150 Pages
Global
From €2565EUR$2,625USD£2,141GBP
€3664EUR$3,750USD£3,059GBP
- Report
- January 2024
- 200 Pages
Global
From €4055EUR$4,150USD£3,385GBP
- Report
- July 2024
- 158 Pages
Global
From €3322EUR$3,400USD£2,773GBP
€4152EUR$4,250USD£3,467GBP
- Report
- February 2024
- 72 Pages
South Korea
From €4885EUR$5,000USD£4,078GBP
- Report
- August 2023
- 1500 Pages
Global
From €8549EUR$8,750USD£7,137GBP
- Report
- January 2023
- 195 Pages
Latin America
From €4885EUR$5,000USD£4,078GBP
- Report
- June 2022
- 55 Pages
India
From €4885EUR$5,000USD£4,078GBP
The NAT Screening market within the context of In Vitro Diagnostics is a segment of the healthcare industry that focuses on the development and commercialization of tests that detect the presence of infectious agents in a sample. These tests are used to diagnose and monitor the spread of infectious diseases, such as HIV, hepatitis, and other viruses. NAT Screening tests are used in a variety of settings, including clinical laboratories, hospitals, and public health departments.
NAT Screening tests are typically performed using a variety of technologies, such as polymerase chain reaction (PCR), nucleic acid hybridization, and enzyme-linked immunosorbent assays (ELISA). These tests are used to detect the presence of specific genetic material in a sample, which can be used to identify the presence of a particular infectious agent.
Some companies in the NAT Screening market include Abbott Laboratories, Becton Dickinson, Cepheid, Hologic, and Roche Diagnostics. Show Less Read more